Wells Fargo & Company MN Reduces Position in COMPASS Pathways plc (NASDAQ:CMPS)

Wells Fargo & Company MN lowered its position in COMPASS Pathways plc (NASDAQ:CMPS) by 48.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 156,748 shares of the company’s stock after selling 145,067 shares during the quarter. Wells Fargo & Company MN owned approximately 0.23% of COMPASS Pathways worth $593,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also modified their holdings of CMPS. Geode Capital Management LLC raised its position in COMPASS Pathways by 160.3% in the 3rd quarter. Geode Capital Management LLC now owns 42,169 shares of the company’s stock valued at $266,000 after purchasing an additional 25,970 shares during the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in COMPASS Pathways by 18.1% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 174,921 shares of the company’s stock valued at $661,000 after purchasing an additional 26,787 shares during the period. Brown University increased its stake in COMPASS Pathways by 194.6% in the fourth quarter. Brown University now owns 214,200 shares of the company’s stock valued at $810,000 after purchasing an additional 141,500 shares during the period. Conservest Capital Advisors Inc. raised its holdings in shares of COMPASS Pathways by 28.9% in the fourth quarter. Conservest Capital Advisors Inc. now owns 13,363 shares of the company’s stock valued at $51,000 after buying an additional 3,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new stake in shares of COMPASS Pathways during the fourth quarter worth about $41,000. 46.19% of the stock is owned by institutional investors and hedge funds.

COMPASS Pathways Trading Up 2.2 %

Shares of CMPS stock opened at $4.19 on Friday. The business’s fifty day moving average price is $3.34 and its 200 day moving average price is $4.13. The firm has a market capitalization of $388.30 million, a PE ratio of -1.90 and a beta of 2.34. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. COMPASS Pathways plc has a 1-year low of $2.49 and a 1-year high of $9.63.

COMPASS Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.01). As a group, sell-side analysts forecast that COMPASS Pathways plc will post -2.33 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CMPS has been the subject of several analyst reports. Stifel Nicolaus began coverage on COMPASS Pathways in a research note on Thursday, February 27th. They set a “buy” rating and a $11.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $45.00 price target on shares of COMPASS Pathways in a research note on Tuesday, March 4th. Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 price objective on shares of COMPASS Pathways in a research report on Wednesday, January 15th. Cantor Fitzgerald restated an “overweight” rating on shares of COMPASS Pathways in a research report on Friday, March 28th. Finally, Canaccord Genuity Group lowered their target price on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a report on Friday, February 28th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $20.20.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.